Gold (GC=F) April futures opened at $5,247.50 per troy ounce on Tuesday, 0.4% higher than Monday’s closing price of $5,225.60. Gold has not opened above $5,200 since Jan. 30. Uncertainty over U.S. tariffs and tensions in the Middle East have fueled gold demand this week. The Supreme Court struck down many of President Trump’s tariffs last Friday, prompting the announcement of new levies supported by a different statute. That 10% tariff went into effect on Tuesday, but it can only remain in place for 150 ...

Donald Trump’s ‘liberation day’ announcement last April sent the stock market into a meltdown - Al Drago/Getty Images Donald Trump’s tariff turmoil has triggered the worst run for private equity since the financial crisis, with the industry returning fewer profits to investors for the fourth year running. Private equity firms distributed 14pc of their net asset value to investors for the second year in a row in 2025, according to a new report from Bain & Co, the management consultancy. This is down from ...

With a market cap of $15.2 billion, Avery Dennison Corporation (AVY) is a global materials science and manufacturing company specializing in pressure-sensitive labeling, packaging materials, and functional materials used across consumer goods, retail, logistics, and industrial markets. Founded in 1935 and headquartered in Mentor, Ohio, the company supplies branding and information solutions that help customers identify, track, and protect products throughout the supply chain. Avery Dennison has substanti ...

Core Insights - Novo Nordisk's Board of Directors is undergoing a revamp, nominating Jan van de Winkel and Ramona Sequeira for a one-year term, pending shareholder approval at the Annual General Meeting on March 26 [1] - The board is also seeking the re-election of existing members, including Lars Rebien Sørensen as chair and Cees de Jong as vice chair [4] Group 1: Board Changes - Jan van de Winkel has over 25 years of experience in the pharma industry, currently serving as CEO of Genmab since 2010, and has held various C-suite roles [2] - Ramona Sequeira has over 30 years of experience in pharma leadership, previously serving as president of Takeda's global portfolio division and currently on the boards of Organon and Edwards Lifesciences [3] - The board's restructuring follows a significant change in October 2025, when seven members resigned due to disagreements with the Novo Nordisk Foundation regarding the board's future composition [6] Group 2: Market Challenges - Novo Nordisk is facing competition from Eli Lilly in the cardiometabolic market, forecasting a sales dip of up to 13% in 2026 due to pricing pressures from the Most Favored Nation (MFN) policy in the US [7] - Despite having a lead in the oral GLP-1RA market with the approval of oral Wegovy (semaglutide), Eli Lilly's orforglipron is expected to enter the market in April 2023, with projected sales of $14.3 billion by 2031 [8] Group 3: Shareholder Influence - The Novo Nordisk Foundation, the majority shareholder, has recommended Helena Saxon for a board position, who has prior experience on the board of Sobi and currently serves on the board of H&M [5]

Core Insights - Novo Nordisk's GLP-1 drug Ozempic gained significant traction after the introduction of Wegovy in 2021, leading to a 60% increase in stock price that year [1] - In 2022, total sales growth reached 18%, with net income growing by 9% due to investments in production capacity; however, 2023 saw a sales surge of 35% and profits up by 55% before facing competition from Eli Lilly's products in 2024 [2] - The stock price peaked above $142 in 2024 but has since fallen to around $47, representing a 67% decline from its peak [3] Sales and Market Dynamics - The introduction of oral versions of Wegovy and Ozempic has reinvigorated interest in Novo Nordisk, with FDA approvals for these new forms occurring recently [5] - Eli Lilly is expected to quickly catch up with its own GLP-1 pills, with an FDA decision on a Mounjaro pill anticipated in the second quarter of the year [6] - Novo Nordisk is aware of the competitive landscape and is likely to intensify efforts to maintain market share in the oral GLP-1 segment [7]

Market Sentiment - The crypto market is currently experiencing extreme fear, with the fear and greed index reaching an all-time low of 5 on February 5 and 12 on February 18, indicating a significant bearish sentiment [2][4] - Bitcoin, Ethereum, and XRP have seen substantial declines, with Bitcoin down 27%, Ethereum down 32%, and XRP down 34% over the last three months, reflecting the overall downturn in the crypto market [6] Fear and Greed Index - The fear and greed index ranges from 0 to 100, where lower values indicate more selling activity and higher values suggest more buying activity and optimism in the market [4] - While the index serves as a momentary snapshot of market sentiment, it may not have long-term relevance for price movements or portfolio diversification strategies [5] Market Conditions - The current low readings on the fear meter often coincide with oversold conditions, suggesting that some crypto assets may be undervalued due to rapid emotional selling [6]

Management highlighted strong franchisee economics and ongoing digital investments as key drivers. New menu innovations, including stuffed-crust pizza offerings, and loyalty program enhancements aim to keep traffic steady and boost repeat orders. Despite inflationary pressures, disciplined cost controls helped margins remain stable.In Q3 fiscal 2025, Domino’s delivered revenue of $1.14 billion, up 6.2% year-over-year (YoY). Net income reached $139.3 million, translating to earnings per share of $4.08. Even ...

In South Africa, the return of Stage 3 load-shedding in February 2025 underscored the fragility of the national grid. Eskom’s ageing units continued to experience repeated breakdowns, with unplanned outages often exceeding 14,000 MW, well beyond the threshold required to avoid rotational blackouts . With reserve margins consistently strained, even minor equipment failures trigger load-shedding, highlighting how the combination of ageing infrastructure, maintenance backlogs, and rising demand leaves little r ...

Comvita has attracted overseas interest as the Manuka honey maker works on a capital raise under its wider recapitalisation programme. In a stock exchange filing today (23 February), the New Zealand-based business reported receiving “credible expressions of interest” from current shareholders and new investors to back and potentially underwrite the proposed fundraising. Comvita said part of this interest had come from "an offshore strategic investor in the food and beverage sector". According to the fi ...

Nike (NYSE: NKE) stock continues to falter as the athletic giant tries to find its footing, but its industry peers aren't doing much better. Nike stock is down 15% over the past year, but newcomer On Holding (NYSE: ONON) is down 11%, and Lululemon Athletica has lost half of its value. Nike and On are two sides of the same coin. Nike represents the established industry leader, while On is the new and exciting start-up. Let's see which one is the better buy today. Will AI create the world's first trillionair ...